Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Intravenous replenishment of fluids and calories in patients who cannot take orally,Maintenance of hydration and electrolyte balance,Treatment of hypovolemia,Prevention of dehydration
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal half-life of infused dextrose is not applicable as glucose is rapidly metabolized; however, exogenous glucose infusion is cleared with a half-life of approximately 15-30 minutes due to insulin-mediated uptake. Sodium and chloride have no defined elimination half-life as they are homeostatically regulated.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the Krebs cycle in cells; sodium and chloride are excreted renally and via sweat; no significant hepatic metabolism.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Dextrose is completely metabolized to carbon dioxide and water, with negligible renal excretion of intact glucose under normal conditions. Sodium and chloride are freely filtered by the glomerulus and undergo variable tubular reabsorption; excess is excreted renally. No biliary or fecal elimination.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: not bound to plasma proteins. Sodium: negligible protein binding. Chloride: not significantly protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose distributes into total body water, approximately 0.55-0.6 L/kg in adults. Sodium and chloride distribute primarily into extracellular fluid, with volumes of distribution of approximately 0.2 L/kg for sodium and 0.25 L/kg for chloride. These reflect rapid equilibration in respective compartments.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% for dextrose, sodium, and chloride. Not applicable for other routes as this formulation is for IV use only.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
GFR <10 m L/min: Avoid or use with caution due to risk of fluid overload and hypernatremia. GFR 10-50 m L/min: Monitor serum sodium and fluid status; adjust rate as needed. No specific dose reduction, but infusion rate may need to be decreased.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment required for Child-Pugh class A or B. For Child-Pugh class C: Use with caution due to potential fluid retention; monitor serum sodium and adjust rate accordingly.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 2-4 m L/kg/hour for children. For neonates, rate may be adjusted to 80-100 m L/kg/day. Do not exceed 25 m L/kg/hour.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients: Start at lower end of dosing range (e.g., 100 m L/hour) and titrate based on fluid status, renal function, and cardiac reserve. Monitor for signs of fluid overload and electrolyte imbalance.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn-derived products. Do not administer to patients with anuria. Use with caution in patients with congestive heart failure, renal failure, or hyperglycemia.
None
Risk of hyperglycemia and hyperosmolarity, especially in diabetic or stressed patients,Monitor serum glucose and electrolytes,Use with caution in renal impairment, heart failure, and increased intracranial pressure,Hypotonic solution; may cause hemolysis if administered rapidly,Do not use if solution is discolored or contains particulates
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to dextrose or corn products,Intracranial or intraspinal hemorrhage,Anuria,Severe hyperglycemia with marked glycosuria,Patients with known allergy to any component
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. However, patients should avoid excessive salt or sugar intake unless directed by a healthcare provider.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. Hyperglycemia or fluid/electrolyte imbalances may pose fetal risks. No first trimester data suggest direct teratogenicity.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Both dextrose and sodium chloride are normal constituents of breast milk. Maternal administration at isotonic and isosmotic concentrations does not alter milk composition measurably. M/P ratio not applicable as endogenous substances. Generally considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Increased plasma volume (30-50%) and glomerular filtration rate during pregnancy may alter pharmacokinetics; however, dextrose and sodium chloride are endogenous substances regulated by homeostasis. No specific dose adjustment required except to monitor and adjust infusion rate based on maternal glucose, hydration status, and electrolyte levels. Pregnancy may unmask glucose intolerance; titrate dextrose infusion to avoid hyperglycemia.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Dextrose 5% and sodium chloride 0.45% is a hypotonic solution. Use cautiously in patients at risk for increased intracranial pressure (e.g., traumatic brain injury) as rapid administration may cause cerebral edema. Avoid in patients with hyperglycemia, as dextrose can worsen glycemic control. Monitor serum sodium closely in patients with impaired renal function or syndrome of inappropriate antidiuretic hormone (SIADH) to prevent hyponatremia.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report symptoms like headache, nausea, confusion, or swelling during the infusion.,Do not consume additional salt or sugar without medical advice while receiving this solution.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.